JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that Joe Hazelton, Dyadic’s President & ...

Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the second quarter of 2025 and will host a corporate update conference call on August 13, 2025 [1] Group 1: Financial Reporting - The company will announce its financial results for Q2 2025 on August 13, 2025 [1] - A conference call will take place at 5:00 p.m. Eastern Time on the same day [2] - Dial-in numbers for the conference call are provided, including a toll-free option and an international number [2] Group 2: Company Overview - Dyadic is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins [1][4] - The company utilizes proprietary gene expression platforms for applications in life sciences, food and nutrition, and industrial biotechnology [1][4] - Dyadic's C1 and Dapibus™ expression systems support flexible and cost-effective manufacturing, forming the basis of its commercial and partnered programs [4]

Core Viewpoint - Dyadic International, Inc. has announced a public offering of 6,052,000 shares of common stock at a price of $0.95 per share, expecting gross proceeds of approximately $5.75 million before expenses [1][2]. Group 1: Offering Details - The public offering is managed by Craig-Hallum Capital Group LLC, and the closing is anticipated on August 1, 2025, subject to customary conditions [1][2]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including product development and sales and marketing [2]. Group 2: Company Background - Dyadic International is a global biotechnology company that focuses on scalable production of precision-engineered functional input proteins for various applications in life sciences, food and nutrition, and industrial biotechnology [1][5]. - The company utilizes proprietary gene expression platforms, specifically its C1 and Dapibus™ systems, to produce high-quality recombinant proteins for partners in multiple markets [5].

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high- value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock. ...

The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission ("SEC") on August 9, 2023 and declared effective by the SEC on August 25, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying pros ...